



PRESS RELEASE • PRESS RELEASE • PRESS RELEASE

NEOVACS CONFIRMS ITS DEVELOPMENT STRATEGY IN THE USA BY PARTICIPATING AT THE AMERICAN CONGRESS OF RHEUMATOLOGY IN BOSTON FROM 15TH TO 19TH OF NOVEMBER

Paris, 12 November 2014 – NEOVACS (Alternext Paris : ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, will participate at the American Congress of Rheumatology in Boston from 15th to 19th of November, strongly confirming its desire to develop itself in the USA.

On the occasion of the worldwide largest Congress of Rheumatology which starts at the end of this week in Boston, Neovacs will be attending with a large booth. It will present and explain the company's technology of therapeutic vaccines inducing the production of polyclonal antibodies.

Pictures of the booth and explanation panels will be online next Monday, 17th of November.

The Clinical Advisory Board for the study in Lupus will meet at that occasion in order to finalize the protocol of the planned multicentric Phase IIb study. The objective of this study will be to demonstrate the clinical efficacy of the Kinoid IFN α in Lupus (SLE). Lupus is a serious autoimmune disease, very invalidating and potentially fatal, which affects more than 5 million people in the world, particularly women. Currently, there is no satisfying therapy available against this disease. The clinical trial will be initiated mid of 2015 in Asia, Europe and America.

During this Congress, Neovacs will also present the results of a study realized with an academic partner, the University Clinic Saint Luc in Brussels, poster 2019, which demonstrates the differential implication of type 1 Interferon in the clinical expressions of Lupus disease and the major importance of IFN α in this pathology, particularly in renal affections.

Finally, Neovacs will make available to the attendants of this Congress, the results presented as a poster during EULAR 2014 in Paris last June.

This study demonstrated the clear superiority of the polyclonal antibodies induced by the administration of IFN α -Kinoid for the neutralization of IFN α , in comparison with monoclonal antibodies.

About Neovacs

Neovacs is a biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by six patent families that run until at least 2023) Neovacs is focusing its development efforts on two active immunotherapies: TNF-Kinoid is being developed for the treatment of TNF-mediated autoimmune diseases such as rheumatoid arthritis and Crohn's disease, whereas IFN α -Kinoid is being developed for the indication of lupus. Neovacs is also conducting preclinical works on IFN α -Kinoid in certain chronic viral infections, VEGF-Kinoid in Age-related Macular Degeneration (AMD) and solid

tumors, and IL-4-Kinoid for the treatment of allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

For more information on Neovacs, visit www.neovacs.fr

Press & Financial Communication France – Publicis

Stéphanie Tabouis
+33 (0) 1 44 82 46 35
stephanie.tabouis@consultants.publicis.fr

Aubane de Gélis
+33 (0) 1 44 82 46 38
aubane.de-gelis@consultants.publicis.fr